Latest Financials News

Ovanti Limited has raised $5.27 million through a discounted placement, aiming to accelerate its global Buy Now Pay Later platform and Super App development with AI integration and merchant expansion.

XRF Scientific posted a 13.8% jump in March quarter revenue to $15.8 million, led by strong international sales and new product shipments. The newly operational India office marks a strategic expansion, setting the stage for further growth.

Larvotto Resources is progressing the Hillgrove Antimony-Gold Project on time and budget, aiming for mid-2026 production amid rising strategic demand for antimony. The project benefits from grid power, ongoing drilling success, and government support for critical minerals.

Magnum Mining names Antonio Vitor Junior as Managing Director to spearhead major drilling campaigns at its Azimuth and Parker projects, aiming to convert promising early rare earth results into a formal resource.

Xenitra Limited has acquired Hong Kong Fukang Trading Co., including key pharmaceutical licenses and ecommerce assets, to fully operationalise its OTC medicine business in Hong Kong and China.

Strategic Energy Resources has locked in a binding joint venture with Sumitomo Metal Mining Oceania to explore its Bulimba Gold Project in northeast Queensland, with Sumitomo able to earn up to 90% through staged commitments over five years.

Qoria Limited and Aura have pushed back their merger timeline to July 2026 amid transaction complexities, with Aura providing a A$10 million unsecured working capital facility to support Qoria through the interim period.

Shine Justice reshuffles its top management as Simon Morrison steps down from Managing Director to Executive Director to spearhead international growth, particularly in its burgeoning mass torts program, while Carolyn Barker AM maintains overall CEO leadership.

Wildcat Resources (ASX: WC8) has expanded its Bolt Cutter Central lithium discovery footprint beyond 2.3km with multiple high-grade spodumene intercepts, while advancing the Definitive Feasibility Study for its Tabba Tabba Project. The company maintains a strong cash position of A$43.3 million as it prepares for further drilling and development milestones.

Orthocell has secured approval for its Remplir™ nerve repair device to be used across 221 U.S. military and veterans hospitals, marking a major step in its U.S. commercial expansion. The approval follows clinical validation in conflict zones, positioning Orthocell to deepen penetration into defence healthcare.

Duratec's joint venture with Ertech has clinched a $281 million contract to upgrade submarine infrastructure at HMAS Stirling, marking a major step in Australia's AUKUS defence preparations.

Nyrada has secured ethics approval to start its Phase IIa trial of Xolatryp in heart attack patients, with recruitment beginning in April 2026. The biotech also bolsters its cash position to AU$6.74 million and pursues new oncology indications.